Fig. 5: ABT-199 (Venetoclax) treatment in vivo reduces tumor burden and extends survival in NSG mice xenografted with ALMC-1 tumors. | Nature Communications

Fig. 5: ABT-199 (Venetoclax) treatment in vivo reduces tumor burden and extends survival in NSG mice xenografted with ALMC-1 tumors.

From: Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics

Fig. 5

a Tumor growth curves of ALMC-1 tumors engrafted in NSG mice, treated with vehicle, venetoclax, or bortezomib. Thicker lines are average tumor size for each treatment (n = 4). b Tumor volume at the indicated number of days post initiation of treatment (n = 4). c Overall survival of mouse cohorts grouped by treatment received. d, e hCD45+ cells from ALMC-1 tumors from vehicle-treated (n = 1), bortezomib-treated (n = 2), and venetoclax-treated (n = 2) mice were BH3 profiled to measure their d overall level of apoptotic priming via sensitivity to the BIM BH3, BID BH3, and PUMA BH3 peptides and their e dependencies on the pro-survival BCL-2 family proteins BCL-2, BCL-XL, and MCL-1. P-values were calculated using two-way ANOVA with Holm–Sidak’s adjustment for b and Log-rank (Mantel-Cox) test to compare survival curves in c.

Back to article page